Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | IDH1 R132H |
Therapy | Radiotherapy + Veliparib |
Indication/Tumor Type | high grade glioma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
IDH1 R132H | high grade glioma | sensitive | Radiotherapy + Veliparib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, treatment with Veliparib (ABT-888) enhanced sensitivity to radiation therapy in immortalized astrocytes expressing IDH1 R132H in culture, resulting in greater decreased colony formation, and in a glioma cell line xenograft model, resulting in both increased tumor regression and survival compared to radiation therapy alone, with a median overall survival of 66 days vs 22 days, respectively (PMID: 32494639). | 32494639 |
PubMed Id | Reference Title | Details |
---|---|---|
(32494639) | Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas. | Full reference... |